Results in Brief



Year ended 31 March	2024 NZ\$M (except as otherwise stated)	2024 Underlying ² NZ\$M (except as otherwise stated)	2025 NZ\$M (except as otherwise stated)	% Change (Reported)	% Change (Constant Currency ¹)	% Change Underlying (Reported)	% Change Underlying (Constant Currency ¹)
FINANCIAL PERFORMANCE	,						
Operating revenue	1,742.8	1,742.8	2,021.0	16%	14%	16%	14%
Cost of sales	(698.4)	(678.4)	(750.1)	7%	7%	11%	10%
Gross profit	1,044.4	1,064.4	1,270.9	22%	18%	19%	16%
Gross margin	59.9%	61.1%	62.9%	296 bps	247 bps	181 bps	129 bps
Selling, general and administrative expenses	(492.8)	(492.8)	(534.4)	8%	8%	8%	8%
Research and development expenses	(198.2)	(198.2)	(226.9)	14%	14%	14%	14%
R&D percentage of operating revenue	11.4%	11.4%	11.2%	-15 bps	8 bps	-15 bps	8 bps
Total operating expenses	(691.0)	(691.0)	(761.3)	10%	10%	10%	10%
Operating profit	353.4	373.4	509.6	44%	36%	36%	28%
Operating margin	20.3%	21.4%	25.2%	494 bps	377 bps	379 bps	260 bps
Revaluation of land	(98.1)	-	-				
Profit before financing and tax	255.3	373.4	509.6	100%	97%	36%	28%
Net financing (expense) / income	(19.6)	(19.6)	(6.3)	-68%	-56%	-68%	-56%
Profit before tax	235.7	353.8	503.3	114%	107%	42%	32%
Tax expense	(103.1)	(89.4)	(126.1)	22%	18%	41%	39%
Profit after tax	132.6	264.4	377.2	184%	180%	43%	30%
Effective tax rate	43.7%	25.3%	25.1%				
Effective tax rate excluding R&D tax credit, revaluation of land and removal of building depreciation	30.5%	30.5%	29.1%				

¹ Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. The company's constant currency framework can be found on the company's website at www.fphcare.com/ccf. The reconciliation to reported results is included within the Financial Commentary section of the Annual Report.

² Underlying financial performance has been presented excluding the impact of abnormal items during the 2024 financial year. For more information, please refer to page 127 of the Annual Report.

Results in Brief (continued)

Year ended 31 March	2024	2025	% Change (Reported)	
	NZ\$M	NZ\$M	(itoponod)	
Revenue by Region:				
North America	806.1	967.2	20%	
Europe	477.3	541.5	13%	
Asia Pacific	368.9	420.8	14%	
Other	90.5	91.5	1%	
Total	1,742.8	2,021.0	16%	
Revenue by Product Group:				
Hospital	1,087.9	1280.3	18%	
Homecare	652.3	739.9	13%	
Core products sub-total	1,740.2	2,020.2	16%	
Distributed and other	2.6	0.8	-69%	
Total	1,742.8	2,021.0	16%	
As at 31 March	2024 NZ\$M (except as otherwise stated)	2025 NZ\$M (except as otherwise stated)	% Change	
FINANCIAL POSITION				
Tangible assets	2,100.8	2,313.6	10%	
Intangible assets ³	180.9	237.2	31%	
Total assets	2,281.7	2,550.8	12%	
Total liabilities	(522.6)	(660.4)	26%	
Shareholders' equity	1,759.1	1,890.4	7%	
Gearing	1.8%	-11.6%	-732%	
Net tangible asset backing (cents per share)	271	284	5%	

2024 2025 Year ended 31 March % Change NZ\$M NZ\$M (except as (except as otherwise stated) otherwise stated) **CASH FLOWS** 429.6 548.6 Net cash flow from operating activities 28% (339.0) Net cash flow (used in) investing activities (103.0) -70% (128.7) Net cash flow (used in) financing activities (268.2) 108% SHARES OUTSTANDING Weighted average basic shares 581,972,373 585,543,359 outstanding Weighted average diluted shares 586,178,934 590,199,636 outstanding Basic shares outstanding at period end 586,139,423 583,963,682 **DIVIDENDS AND EARNINGS PER** SHARE 42.5 Dividends per share (cents) - declared 41.5 2% Basic earnings per share (cents) 22.8 64.4 182%

³ Includes Intangible and deferred tax assets.